SIRION Biotech and Vibalogics partner to offer complete Adeno-Associated Virus (AAV) services

Dow Jones received a payment from EQS/DGAP to publish this press release.

DGAP-Media / 2017-09-29 / 17:20 
 
*NEWS RELEASE* 
 
26 September 2017 
 
*SIRION Biotech and Vibalogics partner to offer complete Adeno-Associated 
Virus (AAV) services* 
 
Munich, Germany - SIRION Biotech GmbH and Vibalogics GmbH, have signed a 
strategic partnership agreement designed to meet demand from gene therapy 
companies for a start-to-finish Adeno-Associated Virus (AAV) service. 
 
The new service offering, which will be available from the beginning of 
2018, will allow the two companies to cater to virtually all customer needs 
for viral vector services, from initial vector engineering and development 
to GMP production. 
 
As part of the collaboration, SIRION Biotech will provide specialist AAV 
technology, while Vibalogics will act as its production partner for 
customers ready to progress to clinical trials. 
 
Dr. Christian Thirion, CTO and founder of SIRION Biotech said: "This step 
will allow us to offer one of the most versatile and complete AAV services 
packages in the world and meet demand for a more streamlined development and 
supply process. We are looking forward to a partnership that will empower 
gene therapy companies to make sure that ingenious new treatments get to the 
patient without delay." 
 
Along with the expanded service offering, the companies will also establish 
new stringent quality levels for pre-clinical virus batches that will 
emulate Vibalogics' GMP production methods. This strategy will ensure that 
pre-clinical research can be conducted with fully scalable products at 
'GMP-like' quality, while maintaining cost and time efficiency. 
 
Dr. Stefan Beyer, Managing Director of Vibalogics said: "We are delighted to 
enter into this partnership and be in a position to offer our customers a 
broader service than we can offer alone. We believe that this is a great 
opportunity for companies in the AAV field to benefit from a seamless 
transition from pre-clinical activities to clinical manufacturing." 
 
SIRION Biotech, based in Munich, is a virus engineering expert specialising 
in viral vector technologies. Using its team of specialists and expertise in 
the biotech industry, the company carries out complex development projects 
to customize AAV dynamics and improve vector tropisms, safety and 
productivity. 
 
Vibalogics, based in Cuxhaven, Germany, offers GMP manufacturing and 
development services for the biopharmaceutical industry and specialises in 
the handling and manufacture of viruses and live bacterial products for 
therapeutic and prophylactic applications. The company is one of the few 
providers of GMP compliant fill and finish services dealing with live 
viruses and bacteria. In addition to GMP manufacturing, Vibalogics offers 
process development, assay development and release testing services along 
with QP release of the clinical batch to complete the chain of activities. 
 
End of Media Release 
 
Issuer: Sirion Biotech GmbH 
Key word(s): Health 
 
2017-09-29 Dissemination of a Press Release, transmitted by DGAP - a service 
of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
614783 2017-09-29 
 
 

(END) Dow Jones Newswires

September 29, 2017 11:20 ET (15:20 GMT)